AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00410384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
Study NCT02459340 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: therapeutic treatment (inpatient and outpatient setting)
Study NCT01649726 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Apnea test - control
Study NCT01649726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apnea test - CPAP
Study NCT01096095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
Study NCT01096095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Phenylbutyrate
Description: Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
Study NCT04471597 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: 5 ml of bupivacaine 0.5% will be installed topically around the ETT using ordinary syringe before the expected end of the surgery, this will be followed by manual ventilation using about the double tidal volume for 6-8 times or more to get air bubbles distributed within the upper airway to anesthetize the oropharynx and spread around ETT to the adjacent mucosal structures (laryngopharynx, larynx, and upper part of the trachea) then the cuff will be inflated to the previous pressure and patient will be mechanically ventilated as usual.
Study NCT01192295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone HCl controlled-release tablets
Description: Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
Study NCT03547986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Duplex Ultrasound (DUS)
Description: Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Duplex Ultrasound
Study NCT03547986 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IVUS with Intraarterial pressure measurement (IAP) if needed
Description: Occurrence of a flow-limiting dissection or residual stenosis will be assessed by standard angiography and Intra-vascular ultrasound associated to Intraarterial pressure measurement if needed
Study NCT00461448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Potassium supplement
Description: Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
Study NCT00461448 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium supplement
Description: Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
Study NCT00630539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Study NCT00630539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 5 mg
Description: 1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Study NCT00630539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 15 mg
Description: 1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Study NCT00630539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene 30 mg
Description: 1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
Study NCT00618358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Sealant System
Description: The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
Study NCT00618358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam/Thrombin
Study NCT02519179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opaque, weighted bottle
Description: This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
Study NCT02519179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clear, conventional bottle
Description: This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
Study NCT02250144 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foot orthoses
Study NCT02250144 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Foot orthoses
Study NCT02668835 — intervention group
Intervention type: DEVICE
Intervention: Non intervention-Monitoring device
Description: Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
Study NCT02668835 — intervention group
Intervention type: GENETIC
Intervention: Non intervention-Genetic testing
Study NCT04127344 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy Intervention
Description: Patients randomized to a music therapy intervention will receive an individualised music therapy intervention. The sessions will last 10-20 minutes and they will be done by music therapist and musician.
Study NCT00696904 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Capsule, see arms for intervention description
Study NCT00696904 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsule, see arms for intervention description
Study NCT02923895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stannous fluoride
Description: 0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
Study NCT02923895 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate
Description: 0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
Study NCT00647140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 18F-L-DOPA PET
Description: PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
Study NCT01072929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
Study NCT01072929 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo, also in tablet form taken orally, once daily in the morning.
Study NCT01008748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Description: NRT for participants who smoke >10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
Study NCT01008748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
Study NCT01008748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
Study NCT01008748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
Study NCT02759198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH23537
Description: Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
Study NCT02759198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Drug: Celecoxib 200mg
Study NCT02759198 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: YH23537 placebo
Description: Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
Study NCT01627236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
Study NCT02656940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 1 - diet rich in n-3 and n-6 PUFA
Description: In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
Study NCT02656940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 2 - diet rich in MUFA
Description: In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
Study NCT02656940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group 3 - Placebo group
Description: Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
Study NCT02698462 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Family history questionnaire
Description: All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
Study NCT03682536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study NCT03613610 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radio-frequency ablation of genicular nerves
Description: Ablation of the genicular nerves for pain relief in advanced knee osteoarthritis
Study NCT03927807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: This study will include 150 pregnant women who fulfill the inclusion criteria and will be subdivided in two groups.~Group1 will receive repetitive hourly dose of oral misoprostol solution equal to 10 microgram up to 12 doses or regular uterine activity.~Group2 will receive oral misoprostol solution every two hours as 20 microgram up to 6 doses or regular uterine activity.
Study NCT02947412 — intervention group
Intervention type: OTHER
Intervention: laparoscopic sleeve gastrectomy
Description: laparoscopic sleeve gastrectomy
Study NCT00815243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Description: Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
Study NCT00815243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Treatment plan
Description: Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
Study NCT02838953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
Study NCT03937791 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 T Cell Receptor (TCR)
Description: One dose of E7 TCR T cells (1x10\^11 cells) will be administered intravenously over 20 to 30 minutes.
Study NCT00815243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment plan
Description: Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
Study NCT00666874 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle changes
Description: Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
Study NCT00666874 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control - general information
Description: General information about healthy food choices and exercise
Study NCT00135733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amevive (Alefacept)
Study NCT00135733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01514500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered s.c. (subcutaneously, under the skin)
Study NCT03682536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: Specified dose on specified days
Study NCT01514500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo (somapacitan)
Description: Single or multiple placebo doses administered s.c. (subcutaneously, under the skin)
Study NCT04688411 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MED-Go App
Description: A novel multifunctional mobile app (MED-Go) to improve adherence to hydroxyurea in patients with sickle cell disease
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Description: Atezolizumab will be administered as intravenous (IV) infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle (every 3 weeks) for 4 cycles during the neoadjuvant treatment phase~Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) every 3 weeks for 16 cycles during the post-operative adjuvant phase
Study NCT02516254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fortified bread
Description: 50 g of fortified bread + placebo daily
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT02516254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplement
Description: vitamin D supplement+ plain bread
Study NCT02516254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: plain bread+placebo
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel 100 mg/m\^2 will be administered intravenously on Days 1, 8, and 15 of each 21 day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT04160728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Work/ rest scenario
Description: For every hour of work, the participants were asked to take 3-10 minutes break in the shade.
Study NCT04160728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydration scenario
Description: Participants were asked to consume at least 750ml of water or ice-slushies for every hour of work
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT04160728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clothing scenario
Description: Participants were asked to wear different types of clothing during the work shift i.e. ventilated garments, white breathable coveralls, clothing with water submerged parts
Study NCT04160728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-carts scenario
Description: Participants that were involved in manual labor by carrying heavy weights were provided with e-carts (automated carrying vehicles)
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin initial target AUC of 6 mg/mL/min will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered intravenously on Day 1 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT03456063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1250 mg/m\^2 will be administered intravenously on Day 1 and 8 of each 21-day cycle for 4 cycles during the neoadjuvant treatment phase
Study NCT04160728 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Business as usual scenario
Description: No interference with the usual work day of the participants
Study NCT04160728 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham evaluation
Description: Participants were monitored during a usual day of work shift while sham measurements were recorded in order for them to get familiarized with the study environment
Study NCT05605431 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Polysomnography
Description: over nightSleep study
Study NCT04047641 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given Intravenous
Study NCT03354975 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experiential Training
Description: Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders.
Study NCT03354975 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training-As-Usual
Description: The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training.
Study NCT01845883 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Deep Brain Stimulation (DBS)
Description: Patients with DBS will participate to the study both when the stimulation is off and on.
Study NCT04559919 — intervention group
Intervention type: OTHER
Intervention: Seizure status
Description: We will collect information on first seizure ever, last seizure ever, number of seizure in last two months.
Study NCT04559919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tests
Description: We will collect results from imaging, electroencephalogram, and laboratory tests.
Study NCT04559919 — intervention group
Intervention type: OTHER
Intervention: Epilepsy
Description: We will collect information on risk factors of epilepsy, cause of epilepsy, epilepsy type/syndrome, medications tried, if the epilepsy is drug resistent, side effects of antiepileptic drugs.